CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK - Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Drinda New Energy powers up IPO for overseas expansion
002865.SHE
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
